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a b s t r a c t 
Mediterranean Carthamus tinctorius (Safﬂower) is used for treatment of inﬂammatory conditions 
and neuropsychiatric disorders. Recently C. tinctorius lignans arctigenin and trachelogenin but not 
matairesinol were described to interfere with the activity of tryptophan-degrading enzyme indoleamine 
2,3-dioxygenase (IDO) in peripheral blood mononuclear cells in vitro . We examined a potential direct 
inﬂuence of compounds on IDO enzyme activity applying computational calculations based on 3D ge- 
ometry of the compounds. The interaction pattern analysis and force ﬁeld-based minimization was 
performed within LigandScout 3.03, the docking simulation with MOE 2011.10 using the X-ray crystal 
structure of IDO. Results conﬁrm the possibility of an intense interaction of arctigenin and trachelogenin 
with the binding site of the enzyme, while matairesinol had no such effect. 
C © 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical 
Societies. Open access under CC BY-NC-SA license.. Introduction 
The herbaceous Asteraceae plant Carthamus tinctorius (Safﬂower) 
as been used in traditional Chinese medicine to promote circula- 
ion and menstruation [ 1 ] and to treat neuropsychological disorders 
uch as major depression [ 2 ]. In the Mediterranean area, C. tinctorius 
xtracts play a role in the treatment of cancer and are known for an- 
ihelmintic, antiseptic, diuretic and febrifugal properties [ 3 ]. Most of 
he clinical conditions mentioned are associated with immune activa- 
ion and inﬂammation which is characterized by speciﬁc biochemical 
lterations. Among them alterations of tryptophan metabolism ap- 
ear to be most prominent. Tryptophan breakdown due to enzyme 
ndoleamine 2,3-dioxygenase (IDO) is involved in several physiologi- 
al and pathophysiological conditions. IDO is an iso-enzyme of trypto- 
han 2,3-dioxygenase (TDO), and both enzymes catalyze the ﬁrst and 
ate limiting step of tryptophan catabolism namely the conversion of   
Abbreviations: GBVI / WSA, generalized-born volume integral / weighted surface 
rea; 5-HT, 5-hydroxytryptamine, serotonin; IDO, indoleamine 2,3-dioxygenase; IFN- 
, interferon- γ; 1-MT, d -1-methyl tryptophan; Kyn / Trp, kynurenine to tryptophan 
atio; MMFF94, Merck Molecular Force Field 94; PBMC, peripheral blood mononuclear 
ells; TDO, tryptophan 2,3-dioxygenase; Treg, regulatory T-cells. 
* Corresponding author. Tel.: + 43 512 9003 70350; fax: + 43 512 9003 73110. 
E-mail address: dietmar.fuchs@i-med.ac.at (D. Fuchs). 
211-5463 c © 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of Europ
ttp://dx.doi.org/10.1016/j.fob.2013.08.008 tryptophan to N -formyl kynurenine. Whereas TDO is mainly located 
in the liver, IDO is more widely distributed in the organism [ 4 ]. During 
immune activation and inﬂammation IDO is mainly up-regulated by 
Th1-type cytokine interferon- γ (IFN- γ), and this is detectable locally 
and systemically by an increased tryptophan breakdown rate as is 
indicated by an increased kynurenine to tryptophan ratio (Kyn / Trp) 
[ 5 ], whereas in healthy conditions, the expression and activity of IDO 
is low. In animal model systems and in vitro , increased tryptophan 
breakdown was found to lead to immune tolerance via the induction 
of regulatory T-cells (Treg) and dendritic cells [ 6 , 7 ]. 
Tryptophan is also the substrate of the serotonin (5- 
hydroxytryptamine, 5-HT) pathway and its breakdown leads to re- 
duced synthesis of serotonin which is related to depression, as ob- 
served, e.g., in cancer patients during treatment with IFNs [ 5 , 8 ]. Ad- 
ditionally, the accumulation of tryptophan catabolites, such as 3- 
hydroxykynurenine, kynurenic acid and quinolinic acid are believed 
to play a role in the pathogenesis of the AIDS-dementia complex, 
Huntington’s disease, Alzheimer’s disease, complex partial seizures, 
depression, anorexia and schizophrenia [ 9 ]. Thus, in neurological dis- 
orders, IDO inhibitors are supposed to reduce the production of the 
neurotoxic tryptophan metabolites [ 10 ]. 
Based on the observations made in patients and the ethnophar- 
macological use of Safﬂower, the three major lignans trachelogenin, 
arctigenin, and matairesinol ( Fig. 1 ) were isolated from C. tinctorius 
extracts and pharmacologically investigated for their ability to in- 
terfere with activation of IDO in freshly isolated peripheral blood 
mononuclear cells (PBMC) [ 11 ]. Arctigenin and also trachelogenin ean Biochemical Societies. Open access under CC BY-NC-SA license.
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Fig. 1. Chemical structures of compounds trachelogenin (1), arctigenin (2) and 
matairesinol (3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Arctigenin ﬁtted into the active site of IDO. Yellow spheres signify hydrophobic 
interactions between the molecule and the binding pocket. The blue cone stands for a 
metal bond between the lactone ring and the iron of the heme group. The red arrows 
mark hydrogen bond acceptors between Cys129 and a phenolic hydroxyl group and 
Ser235 and an aromatic methoxy group. 
Fig. 3. (A) Docking pose of trachelogenin inside the IDO active site. Yellow spheres 
show hydrophobic parts of the molecule. Red arrows mark hydrogen bond acceptors, 
the green arrow marks a hydrogen bond donor. The hydrogen bonds to Ser263 and 
Ala264 stabilize a position farther removed from the iron compared to arctigenin. (B) 
The missing methoxy group in matairesinol leads to a loss of stabilization, because the 
hydrogen bond to Ser235 is not formed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 exerted a signiﬁcant and dose-dependent effect to suppress trypto-
phan breakdown in the PBMC model, whereas matairesinol was only
weakly effective [ 12 ]. Because of the relatively strong effect of com-
pounds on tryptophan breakdown, we became interested to simulate
possible direct interaction of the lignans with IDO, so a docking sim-
ulation was performed. 
2. Methods 
During the docking simulation the previously energetically mini-
mized molecules were placed within the binding pocket of a protein,
generating a set of energetically favorable poses. These poses are then
ranked according to a score that the docking program assigns to each
pose, estimating the binding free energy. The best ranked pose of each
molecule was then further optimized and a three dimensional repre-
sentation of its interaction pattern, a pharmacophore, was calculated
to analyze the structure–activity relationship. 
The possible direct interaction of the three lignans with IDO
was simulated, 3D geometries of trachelogenin, arctigenin, and
matairesinol were calculated with Discovery Studio [ 13 ] and ener-
getically minimized with Omega 2.2.1. [ 14 ]. The docking simulation
was performed with the software package MOE 2011.10 [ 15 ] using
the X-ray crystal structure of IDO (Protein Data Bank entry 2d0t ) [ 16 ].
A pharmacophore of the metal binding feature was generated within
LigandScout 3.03 [ 17 ] based on the ligand (4-phenyl-imidazole) co-
crystallized in the crystal structure and used as a constraint in the
docking simulation. This means that the docked ligand must form a
coordinated interaction with the heme iron ion from the IDO active
site. For the docking, the A chain of 2d0t, which was crystallized as
a dimer, was used. The original ligand 4-phenyl-imidazole, the two
co-crystallized detergent molecules of 2-[ N -cyclohexylamino]ethane
sulfonic acid, and water were removed. The binding site of the origi-
nal ligand was chosen for the docking. The program deﬁnes the open
space in the binding pocket with so called alpha spheres that rep-
resent available atom positions. Placement was done by the triangle
matcher algorithm using standard settings. The triangle matcher al-
gorithm generates poses by aligning triplets of ligand atoms with
triplets of alpha spheres to ﬁnd possible binding orientations of the
ligand within the binding site. 
Rescoring was performed with London [ 18 ] and GBVI / WSA
(Generalized-Born Volume Integral / Weighted Surface area) [ 19 ] scor-
ing functions to rank the resulting poses of each molecule. The London
scoring function estimates the free energy of a pose by forming a sum
of energy term (considering ligand ﬂexibility, H-bonds and desolva-
tion) and geometric imperfections. The GBVI / WSA estimates the elec-
trostatic solvation using a weighted solvent-accessible surface area.
For structure activity analysis the best ranked docking pose of each
molecule was energetically minimized within LigandScout using the
Merck Molecular Force Field 94 (MMFF94) force ﬁeld for optimiza-
tion of the intermolecular interactions. 3D Protein–ligand interactionpatterns (pharmacophores) were automatically generated using de-
fault settings. The ﬁnal structure–activity relationship investigation
was based on these pharmacophores and not on the absolute dock-
ing scores, due to their well known limited quantitative reliability,
especially in small datasets [ 20 ]. 
3. Results and discussion 
In order to suggest a binding mode for the three ligands, the com-
pounds were docked and energetically minimized into the active site
of human IDO [ 16 ] ( Figs. 2 and 3 ). For arctigenin the lactone ring was
placed very close to the catalytic iron, forming a metal binding fea-
ture that explains the strong activity. This pose was stabilized by two
hydrogen bonds to Ser235 and Cys129 on each side of the molecule.
Trachelogenin was placed in a similar pose, but due to hydrogen bonds
between the lactone hydroxyl group and Ser263 / Ala264, the lactone
was disposed from its ideal interaction geometry with the iron, pos-
sibly explaining the loss in activity ( Fig. 3 A). Compound matairesinol
did not form the hydrogen bond with Ser235 and was less stabilized
within the pocket ( Fig. 3 B). 
The computational calculations conﬁrmed the possibility of an in-
tense interaction of two of out of the three lignin compounds with
the binding site of the enzyme, and this was true for arctigenin and
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Rrachelogenin only while matairesinol had no such effect. So even 
n the case when the structural differences between the three com- 
ounds appeared to be small at ﬁrst glance, the interaction of them 
ith the IDO binding site declined drastically. Thereby it is of par- 
icular interest to note that the dose-dependent suppressive effects 
hich were observed in the in vitro test system of human PBMC were 
uite similar to the results of the calculations: also in PBMC arctigenin 
ad the strongest inﬂuence on IDO activity followed by trachelogenin 
hereas matairesinol had no relevant effect. The calculated 50% in- 
ibitory concentration (IC 50 value) was 26.5 μmol / L for arctigenin 
ollowed by trachelogenin (IC 50 = 57.4 μmol / L). Matairesinol showed 
nly weak suppressive effects, decreasing KYN / TRP signiﬁcantly only 
t a 193 μmol / L concentration. Moreover, IC 50 concentration of arcti- 
enin was only approximately 2.5-fold higher than that of the classical 
DO inhibitor d -1-methyl tryptophan (1-MT) with and IC 50 of 9.3 μM 
 12 ]. 
Molecular modeling calculation results showed that arctigenin 
nd to a lesser extent also trachelogenin strongly interact with the 
DO binding site, whereas matairesinol was predicted to be less stabi- 
ized within the binding pocket. Especially a hydrogen bond between 
he ligand and Ser235 was predicted as crucial for activity. Any effect 
f arctigenin and possibly also of trachelogenin to directly inhibit IDO 
ctivity would have several therapeutic consequences for antidepres- 
ant and immunomodulatory treatment strategies. It might explain 
reatment effects observed with C. tinctorius extracts in traditional 
edicine. However, further studies are needed to clarify this point 
nd the possible application of arctigenin as an IDO inhibitor with 
dditional immunomodulatory properties needs to be further tested 
n appropriate animal model systems. 
Several natural products such as curcumin or reservatrol have 
een tested for IDO inhibitory activity [ 21 , 22 ]. However, most of pub- 
ished work employed assays based on cellular models like the hu- 
an peripheral blood mononuclear cells (PBMC) assay [ 11 , 12 , 21 , 22 ], 
hich was used also in this study and can detect a general effec- 
iveness on IFN- γ-induced biochemical pathways like IDO but no di- 
ect inﬂuence of compounds on IDO is demonstrable. In most cases 
he suppression of tryptophan breakdown can be referred to an ef- 
ect of compounds on IDO expression when the production of pro- 
nﬂammatory cytokines like IFN- γ becomes diminished. Therefore 
n most studies also parallel suppression of neopterin production is 
emonstrable. From a structural perspective the lactone moiety can 
een observed in some other IDO inhibitory compounds, like war- 
arin, coumarin and garvin B [ 23 ]. The lignan scaffold itself was (to 
ur knowledge and recent literature search) not known to act on IDO 
reviously. 
The inhibitory effect of compounds on IDO cannot imply 
 similar inﬂuence on tryptophan 2,3-dioxygenase (TDO), be- 
ause structural homology between TDO and IDO is rather lim- 
ted, Uniprot identity 12.357%, ( http: // www.uniprot.org / uniprot / 
query = reviewed%3Ayes ), ClustalW alignment score −14 ( http: // 
ww.ebi.ac.uk / Tools / msa / clustalw2 / ). While both the enzymes act 
ia an activated heme, the binding pocket anatomy is very different 
 24 , 25 ]. We assume it is unlikely that compounds like arctigenin or 
rachelogenin would also bind to TDO. 
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